Metoclopramide Use in Pediatrics

Introduction to Metoclopramide Safety

• The American Academy of Pediatrics guidelines establish that there is insufficient evidence to support the routine use of metoclopramide in infants or older children with gastroesophageal reflux disease (GERD), and the medication has a black box warning from the FDA due to significant adverse effects 1, 2, 3

Adverse Effects

• Extrapiramidal reactions occur in 11-34% of pediatric patients treated with metoclopramide, including somnolence, restlessness, and acute dystonic reactions 1, 2

Efficacy of Metoclopramide

• A meta-analysis of 7 randomized controlled trials in patients under 2 years with GERD confirmed a decrease in symptoms, but clearly at the cost of significant adverse effects 1, 2
• Randomized controlled trials with placebo in infants have not demonstrated superiority of proton pump inhibitors over placebo for reducing irritability, questioning pharmacological treatment in general 1

Alternative Treatments

• For pediatric GERD, dietary and postural modifications as first-line treatment, and proton pump inhibitors (omeprazole, lansoprazole, esomeprazole) for patients ≥1 year with documented esophagitis 1
• For chemotherapy-induced nausea and vomiting, 5-HT3 antagonists (ondansetron 5 mg/m² or 0.15 mg/kg, granisetron 0.01 mg/kg) combined with dexamethasone for high or moderate emetogenic potential chemotherapy 4

Precautions for Metoclopramide Use

• If metoclopramide is considered in exceptional circumstances, limit duration to less than 12 weeks 5
• Regular neurological monitoring for signs of extrapyramidal symptoms 6
• Avoid use in patients with seizure disorders (contraindicated by FDA) 6